BioCentury | Dec 5, 2020
Product Development

Cortexyme’s Alzheimer’s therapy passes futility analysis, but investors aren’t impressed

Cortexyme’s atuzaginstat cleared a major hurdle in its Phase II/III trial for Alzheimer’s disease, passing a planned futility analysis. However, the criteria for passing only required not performing worse than placebo, which apparently didn’t give investors...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...will be required for ziltivekimab to gain approval. Novo Nordisk will also obtain rights to COR-003...
...Apolipoprotein C-III GLP-1 - Glucagon-like peptide-1 IL-1β - Interleukin-1β IL-6 - Interleukin-6 Paul Bonanos, Associate Editor ziltivekimab (COR-001) Novo...
BioCentury | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
BioCentury | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

...Lundbeckfonden Ventures, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
BioCentury | Jan 25, 2019
Clinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
BioCentury | Jan 24, 2019
Preclinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
BioCentury | Aug 10, 2018
Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

...Phase III data Milestone: Additional Phase III data (1Q19); Phase III data (1Q19) Chris Lieu Recorlev, levoketoconazole (COR-003...
Items per page:
1 - 10 of 445
BioCentury | Dec 5, 2020
Product Development

Cortexyme’s Alzheimer’s therapy passes futility analysis, but investors aren’t impressed

Cortexyme’s atuzaginstat cleared a major hurdle in its Phase II/III trial for Alzheimer’s disease, passing a planned futility analysis. However, the criteria for passing only required not performing worse than placebo, which apparently didn’t give investors...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...will be required for ziltivekimab to gain approval. Novo Nordisk will also obtain rights to COR-003...
...Apolipoprotein C-III GLP-1 - Glucagon-like peptide-1 IL-1β - Interleukin-1β IL-6 - Interleukin-6 Paul Bonanos, Associate Editor ziltivekimab (COR-001) Novo...
BioCentury | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
BioCentury | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

...Lundbeckfonden Ventures, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BioCentury | Feb 15, 2019
Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
BioCentury | Jan 25, 2019
Clinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
BioCentury | Jan 24, 2019
Preclinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
BioCentury | Aug 10, 2018
Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

...Phase III data Milestone: Additional Phase III data (1Q19); Phase III data (1Q19) Chris Lieu Recorlev, levoketoconazole (COR-003...
Items per page:
1 - 10 of 445